People with secondary progressive multiple sclerosis who take the drug siponimod for two years show an improvement in thinking skills, a new study has found. Siponimod, sold as Mayzent, was approved ...

The chronic progressive multiple sclerosis market size is anticipated to grow during the forecast period (2025–2034). According to DelveInsight's analysis, this growth is expected to be driven by the ...

Inspiratory muscle training (IMT) provides significant benefits to patients with advanced multiple sclerosis (MS), and those benefits are retained 8 weeks after cessation of training, according to a ...

A new multiple sclerosis (MS) drug, siponimod (Mayzent), significantly improves cognition for patients with advanced disease, new research shows. Results of a randomized placebo controlled trial ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

When the first spasm hit, it was sharp, sudden, and paralyzing. Tamika Luciano thought her life was ending. The entire left side of her body seized. Her face tightened, her limbs stiffened, and for ...

In the brains of people that suffer from long-term multiple sclerosis (MS), inflammatory cells are not entering the brain via the bloodstream anymore. Instead, the cells arise from local memory cells ...

Four in 10 people with advanced multiple sclerosis, or MS, are emotionally abused by someone responsible for caring for them, reports a study led by the University of California, Riverside. Further, ...

Four in 10 people with advanced multiple sclerosis, or MS, are emotionally abused by someone responsible for caring for them, reports a study led by the University of California, Riverside. Further, ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

In a nationwide survey of adults with advanced multiple sclerosis (MS), more than half reported being mistreated by their caregiver. It is believed to be the first published survey to document the ...

The market size for chronic progressive multiple sclerosis in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest chronic progressive multiple ...